Skip to main content
Signal8
Launch Terminal

Climb Bio, Inc. (CLYM)

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Climb Bio, Inc. logo

Climb Bio, Inc.

NASDAQ:CLYMHealthcare
-0.77%$10.25
AH$10.25+0.00%vs close
Mkt Cap$588.72M
Float38.28M
O/S57.44M
Vol
$ Vol
RVOL
Inst Own98.2%
Earnings
Dilution
Climb Bio, Inc. logoNASDAQ:CLYM$10.25-0.77%
Upcoming Catalysts
  • CLYM116/MIL116READOUT
    Cash runway at this date: 2yr
    First half of 2027~34w8-K
  • CLYM116READOUT
    Cash runway at this date: 2yr
    First half of 2027~34w8-K
  • budoprutugREADOUT
    Cash runway at this date: 23mo
    2027~60w8-K
Phase Distribution
8 lead-sponsored trials·5 active·3 completed
Early Phase 11
Phase 12
Phase 1/22
Phase 23

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2
    Completed

    Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain

    ETX-018810, Placebo

    Diabetic Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy

    Enrollment
    167
    Start
    Nov 2020
    Primary Completion
    Feb 2022
    Completion
    Feb 2022
    NCT04688671
  • Phase 2
    Completed

    Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain

    ETX-018810, Placebo

    Lumbosacral Radiculopathy

    Enrollment
    149
    Start
    Jan 2021
    Primary Completion
    May 2022
    Completion
    May 2022
    NCT04778592
  • Phase 2
    Recruiting

    A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

    budoprutug

    Primary Membranous Nephropathy

    Enrollment
    45
    Start
    Aug 2025
    Primary Completion
    Oct 2027est.
    Completion
    Oct 2027est.
    NCT07096843
  • Phase 1/2
    Recruiting

    A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

    Budoprutug

    Immune Thrombocytopenia (ITP), ITP +3

    Enrollment
    24
    Start
    Jun 2025
    Primary Completion
    Aug 2027est.
    Completion
    Aug 2028est.
    NCT07043946
  • Phase 1/2
    Recruiting

    A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

    Budoprutug

    Systemic Lupus Erthematosus

    Enrollment
    30
    Start
    Jun 2026
    Primary Completion
    Sep 2027est.
    Completion
    Sep 2027est.
    NCT07564596
  • Phase 1
    Recruiting

    A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

    Budoprutug

    Systemic Lupus Erythematosus

    Enrollment
    30
    Start
    Jul 2025
    Primary Completion
    Apr 2027est.
    Completion
    Apr 2027est.
    NCT07011043
  • Phase 1
    Recruiting

    A Phase 1 Study of CLYM116 in Normal Healthy Volunteers

    CLYM116, Placebo

    Healthy Volunteers

    Enrollment
    48
    Start
    Dec 2025
    Primary Completion
    Jul 2026est.
    Completion
    Sep 2026est.
    NCT07248865
  • Early Phase 1
    Completed

    A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers

    Budoprutug, Placebo

    Healthy Volunteers

    Enrollment
    30
    Start
    Aug 2025
    Primary Completion
    Apr 2026
    Completion
    Apr 2026
    NCT07090655
Search ClinicalTrials.gov for “Climb Bio”